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OBJECTIVES: Quantify how anticoagulant (INR) monitoring is
delivered in the UK NHS and understand the impact on general
practice. METHODS: GPs subscribing to an online medical
portal completed an electronic survey on delivery of INR moni-
toring for their AF patients (Sept 2004). RESULTS: GPs (n =
171) reported a mean of 122 patients with AF per practice, with
55% receiving anticoagulation. Most patients are monitored
every month (50%) or more frequently (34%). Bloods are taken
most commonly in general practice, either at a standard appoint-
ment (40%) or practice anticoagulation clinic (21%); the
remainder at the hospital (36%) or at home (3%). Future war-
farin dose is determined by the hospital (59%), GP (28%) or a
nurse (14%) and then communicated to the patient by hospital
staff (59%), nurse (20%), receptionist (15%) or GP (6%).
Patients either wait for results and dosage instruction (27%), or
receive these by telephone (32%), post (21%) or post and tele-
phone (19%). Delays in patients commencing anticoagulation
due to capacity of secondary care system were reported by 48%
of GPs. In the 32% of GPs running a primary care anticoagula-
tion clinic some were motivated by payments for the provision
of additional services (25%) or a specialist interest (16%) but
most were addressing a lack of centralised service i.e. hospital
inaccessible (27%), no hospital or community outreach service
(16%), hospital and/or outreach full (15%). Similar reasons were
given by the 55% of practices that monitored patients in prac-
tice appointments. Despite a monthly mean of 42 practice
appointments for monitoring, GPs felt any more than 28 per
month were compromising other clinical workload. CONCLU-
SIONS: INR monitoring is complex involving a mixed
primary/secondary care model. Availability and capacity issues
in centralised monitoring clinics are the most common reason
for primary care monitoring and this appears to affect other
primary care clinical workloads.
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OBJECTIVES: Treatment guidelines are an important source for
estimation of resource use in pharmacoeconomic models. Obser-
vance of recommendation in clinical practice is a possible
element of uncertainty in the assessment of the results. For pre-
vention of stroke in patients with nonvalvular atrial ﬁbrillation
(AFib) a number of national and international guidelines exist.
Up to now there was a lack of studies which analysed the use of
guidelines in prevention of stroke in Germany. METHODS: A
telephone interview was conducted with a cross-section of GPs,
internists and cardiologists randomly selected from a sub-set of
7072 out of the 59,953 ofﬁce-based physicians of these special-
ties in Germany. A total of 75 completed surveys (15.1% of 498
eligible respondents) were completed. Beside questions on
knowledge of the treatment guidelines the physicians were
requested to assess three case vignettes with need of primary and
secondary prevention strategies. RESULTS: A total of 22% of
the physicians stated that they didn’t know the national recom-
mendations for stroke prevention. Especially GPs were unin-
formed. Only 66% of the GPs shared the opinion that guidelines
are helpful for their daily clinical practice. On the basis of pre-
sented ﬁctive patients the physicians showed a high degree of
uncertainness. The unambiguous cases were better rated by GPs,
whereas more cardiologist and internists proposed treatments
according to the guidelines in the more complex patients. In 
the primary prevention of stroke half of the respondents assed
treatments with ASS in contrast with the guidelines as sensibly.
In general physicians with higher qualiﬁcation had better 
knowledge, but deﬁcits exist independently from specialty. 
CONCLUSION: Results show heterogeneous use of treatment
guidelines by German ofﬁce-based physicians. In Germany, treat-
ment guidelines don’t reproduce the clinical practice and should
be used as a reference in pharmacoeconomic studies with
caution.
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OBJECTIVE: Vitamin K antagonists (VKAs) have a narrow ther-
apeutic window and numerous drug and food interactions and
therefore require frequent INR monitoring. This study aimed to
estimate VKA treatment related costs in patients with chronic
nonvalvular atrial ﬁbrillation (NVAF). METHODS: Data were
collected as part of the French arm of ISAM—International
Study of Anticoagulation Management. Cost analysis was from
a societal perspective and limited to direct medical costs. A ran-
domly selected sample of general practitioners (GPs) and cardi-
ologists (43GPs, 20 cardiologists) established a register of all
patients who had received at least 60 consecutive days of VKA
treatment for chronic NVAF in the preceding year. Study data
came from medical records and patient interviews. VKA treat-
ment related costs included INR tests, blood sample draws,
physician consultations, nurse cost and VKA related hospitali-
sations. Drug costs were not considered. RESULTS: Of 278
patients interviewed, 264 patients had at least two consecutive
INR results within the study period. In total, 3,026 INR tests
were collected over a cumulative follow-up time of 188.4 years.
The mean cost for INR tests was €164.8/patient/year (ppy);
41.2% of blood samples were taken at the patient’s home by a
nurse, with a mean driving distance of 4.6km, representing an
additional cost of €6.3 for each INR taken at home (average
€41.5/ppy). VKA treatment generated 630GP and 171 cardiol-
ogist face-to-face consultations, at a cost of €87.8/ppy. Of 71
hospitalisations reported, 13 were judged attributable to VKAs
by an event adjudication committee. These hospitalisations
added a further €193.1/ppy. CONCLUSIONS: The annual cost
of ambulatory VKA follow-up was €294.1 per patient. VKA
related hospitalisations in this patient sample added €193.1, but
the exclusion of patients unable to be interviewed may have
resulted in underestimation of costs associated with severe and
fatal adverse events (stroke).
